Study explores the history and current state of psychedelic research for treating substance abuse disorders, highlighting challenges like restrictive policies, lack of funding, and the need for recognition of traditional and modern therapeutic practices.
Arrowhead shelves one cardiometabolic drug candidate, focuses on another
On Tuesday, Arrowhead Pharmaceuticals said it will shift focus to its experimental cardiometabolic drug plozasiran and will deprioritize its work on zodasiran, emphasizing the need
June 26, 2024